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Abstract
Human leukotriene A4 hydrolase (hLTA4H) is a bi-functional enzyme catalyzes the hydrolase and aminopeptidase functions
upon the fatty acid and peptide substrates, respectively, utilizing the same but overlapping binding site. Particularly the
hydrolase function of this enzyme catalyzes the rate-limiting step of the leukotriene (LT) cascade that converts the LTA4 to
LTB4. This product is a potent pro-inflammatory activator of inflammatory responses and thus blocking this conversion
provides a valuable means to design anti-inflammatory agents. Four structurally very similar chemical compounds with
highly different inhibitory profile towards the hydrolase function of hLTA4H were selected from the literature. Molecular
dynamics (MD) simulations of the complexes of hLTA4H with these inhibitors were performed and the results have provided
valuable information explaining the reasons for the differences in their biological activities. Binding mode analysis revealed
that the additional thiophene moiety of most active inhibitor helps the pyrrolidine moiety to interact the most important
R563 and K565 residues. The hLTA4H complexes with the most active compound and substrate were utilized in the
development of hybrid pharmacophore models. These developed pharmacophore models were used in screening chemical
databases in order to identify lead candidates to design potent hLTA4H inhibitors. Final evaluation based on molecular
docking and electronic parameters has identified three compounds of diverse chemical scaffolds as potential leads to be
used in novel and potent hLTA4H inhibitor design.
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Introduction
A ubiquitously present 64 kDa metal (Zn
2+) containing cytosolic
human leukotriene A4 hydrolase (hLTA4H) is a bi-functional
enzyme with epoxide hydrolase and aminopeptidase activities
utilizing the same Zn present active site [1]. The development and
regulation of inflammation are maintained by a complex network
of variety of cellular and soluble factors. These factors majorly
contain eicosanoids (structurally similar paracrine hormones
produced along the arachidonic acid (AA) pathway) which include
the prostaglandins, the leukotrienes (LT), and the lipoxins [2]. The
LT are a group of lipid mediators associated with acute and
chronic inflammatory diseases particularly asthma, rhinitis, and
atherosclerosis [3–5]. Biosynthesis of LT promotes the phosphor-
ylation and membrane translocation of cytosolic phospholipase A2
(cPLA2) and 5-lipoxygenase (5-LO) which are the major enzymes
in AA pathway. The cPLA2 releases the AA from membrane lipids
followed by the action of 5-LO enzyme assisted by five-
lipoxygenase activating protein (FLAP) to form the unstable
epoxide LTA4. This key intermediate is subsequently converted in
to LTB4 and LTC4 by the hydrolase activity of LTA4H and by
glutathione transferase activity of LTC4 synthase (LTC4S)
enzymes, respectively [6]. The very little known aminopeptidase
activity of LTA4H has recently speculated that the enzyme may
process peptides related to inflammation and host defense [7,8].
The LTB4 is a potent pro-inflammatory activator of inflammatory
responses mediated through G-protein-coupled receptors, namely,
BLT1 and BLT2. The LTB4 plays an important role in
amplification of many inflammatory disease states such as asthma
[9], inflammatory bowel disease [10], chronic obstructive
pulmonary disease [11,12], arthritis [13,14], psoriasis [15], and
atherosclerosis [16]. It is also recently reported that increased
production of LTB4 is associated with the increased risk for
myocardial infarction and stroke [17]. Therefore, a therapeutic
agent that inhibits the response of cells to LTB4 or the biosynthesis
of LTB4 may be useful for the treatment of various inflammatory
conditions. Inhibition of hLTA4H as therapeutic strategy is
exemplified by the development of multiple inhibitors from
different chemotypes [17–22]. In the development of LTA4H
inhibitors over the past 15–20 years, the early approaches were
based on the natural substrate followed by the utilization of
already known inhibitors of zinc-containing proteins. These
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peptide analogs containing zinc-chelating moieties [23]. Many 3D
crystal structures of LTA4H enzyme bound with diverse inhibitors
were determined and available in protein data bank (PDB).
However, the substrate (LTA4) bound crystal structure has not
been solved yet and that prevents the deeper insight of structural
behavior of the enzyme to accommodate the long chain fatty acid.
The enzyme-inhibitor crystal structure complexes provide details
to understand the inhibitor binding mode and the structural
changes upon inhibitor binding. The 3D structure of LTA4H
enzyme is comprised of three distinctive domains, namely, C-
terminal, N-terminal, and a central catalytic domain. The N-
terminal domain (residues 1–207) is composed of a large seven-
stranded mixed b-sheet and two smaller b-sheets whereas the C-
terminal domain (residues 451–610) is formed by two layers of
parallel a-helices in which the inner layer contains five and outer
layer contains four arranged in anti-parallel manner. The catalytic
domain that is made of residues between 208 and 450 is
surprisingly sharing high structural homology to the bacterial
protease thermolysin [24,25]. In terms of sequence identity, their
similarity majorly confined to the zinc binding motif (HEXXH-
X18-E). This catalytic domain consists of two lobes including one
main a-helical and one mixed a-b lobe. The Zn
2+ site is present
between these lobes and the residues H295, H299, and E318 from
these lobes co-ordinate with the metal ion (Figure 1). During the
binding of substrate or inhibitor, the epoxide group or other
groups possibly form co-ordinate bonds with this metal ion [25].
Though the Zn
2+ binding site is formed by residues from the
catalytic domain the substrate and inhibitor bind the whole stretch
of the active site pocket, which is 6–7 A ˚ wide and 15 A ˚ deep
hydrophobic cavity present at the interface of all three domains
[25]. From the X-ray crystal structures of LTA4H enzyme, a
positively charged site was formed by R563 and K565 residues was
identified in the active site cavity located at the interface of all
three domains. These positively charged residues present in the
first turn of an a-helix pointing towards the active site. In the
proposed binding mode of LTA4, the substrate, these charged
residues formed electrostatic interactions with the carboxylate
group of LTA4. These direct electrostatic interactions were also
observed in the X-ray crystal structures in complex with inhibitors
possessing carboxylate group or similar chemotypes [26,27]. The
role of these residues as putative carboxylate recognition sites in
LTA4H were reported by a site-directed mutagenesis combined
with x-ray crystallography and inhibition studies. Among these
residues, R563 is required to position the substrate along the
catalytic elements of the active site and thereby facilitates the
epoxide hydrolase activity of the enzyme [28]. The mutagenetic
replacements of R563 completely abolished the epoxide hydrolase
activity of LTA4H indicated the importance of this residue
whereas the mutation of K565 has shown variable results. Another
report showed that the mutagenetic replacements of E271
abrogate both catalytic activities (hydrolase and aminopeptidase)
of the enzyme [29]. A previous study has shown the considerable
differences in terms of LTA4H inhibitory activity of very similar
chemical compounds [17]. We focused on these results and
performed molecular dynamics (MD) simulations of LTA4H and
Figure 1. Overall 3D structure of hLTA4H enzyme (PDBcode: 3FH7) representing the three distinct domains and the zoomed view
clearly shows the important catalytic residues. The bound inhibitor is shown in colored surface.
doi:10.1371/journal.pone.0034593.g001
Hybrid Pharmacophore Model for hLTA4H Inhibitors
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34593these inhibitor complexes as the results can be used to understand
about the essential molecular components to bind the active site of
the enzyme with high affinity. The enzyme-substrate and -
inhibitor complexes were prepared using molecular docking when
their crystal structures are not available. Interesting results were
observed during the investigation of molecular trajectories
obtained from the MD simulations. The binding modes, structural
changes, intermolecular hydrogen bonds, and interaction energy
calculations have revealed the molecular interactions explaining
the differences in the biological activities of the inhibitors. Two
hybrid pharmacophore models were developed using MD refined
enzyme-substrate and -inhibitor complexes. The insights acquired
from the present study may be useful in designing novel LTA4H
inhibitors as potent anti-inflammatory agents.
Materials and Methods
Selection of inhibitors and enzyme-inhibitor complex
models
Four inhibitors, namely, C5, C13, C14, and C15 of similar
chemical structures but with highly varying LTA4H inhibitory
profiles were identified from the literature (Figure 2) [17]. The
LTA4H-inhibitor complexes were prepared for the MD simula-
tions to investigate the structural details to address the observed
differences in inhibitory activity profiles. The crystal structures of
LTA4H complexed with C5 and C14 (PDB codes 3FH8 and
3FH5, respectively) were already available in PDB and these
structures were directly used in MD simulations. As the crystal
structures of C13 and C15 are not solved yet, crystal structures of
LTA4H bound with inhibitory molecules similar to C13 and C15
were utilized in preparing their complexes [17,30]. All the crystal
structures were checked for their correctness with regard to their
full length, added fragments, and structure of the bound inhibitors.
All the selected crystal structures were missing four N-terminal
amino acids in their structures and these missing regions were built
using Accelrys Discovery Studio 2.5 (DS) before using them in MD
simulations. The C13 is the ‘S’ isomer of C14 and therefore the
bound conformation of C14 in 3FH5 was modified to represent
C13 by changing its stereochemistry. In case of the most active
compound C15, the very similar compound present in 3FUN was
modified by removing the carbonyl oxygen atom present between
the two phenyl groups. Along with these four LTA4H-inhibitor
complexes LTA4H-substrate (LTA4) complex system was also
prepared using 3FUN to be used in this study to compare with the
structural details of inhibitor complexes. The chemical structure of
LTA4 was sketched and docked into the active site of the average
structure prepared from 5 ns MD simulation of LTA4H apoform.
Molecular dynamics simulations
Initial coordinates for the protein atoms were taken from the
complex structures of LTA4H-inhibitor, substrate complexes, and
apoform. The protonation states of all ionizable residues were set
to their normal states at pH 7. Six MD simulations were
performed for systems including apoform, inhibitors and substrate
complexes. All MD simulations were performed with GRO-
MOS96 forcefield using GROMACS 4.5.3 package running on a
high performance linux cluster computer [31,32]. During the MD
simulations, all the protein atoms including divalent metal ion
(Zn
2+) were surrounded by a cubic water box of SPC3 water
molecules that extended 10 A ˚ from the protein and periodic
boundary conditions were applied in all directions. The systems
were neutralized with Na
+ and Cl
2 counter ions replacing the
water molecules and energy minimization was performed using
steepest descent algorithm for 10,000 steps. A 100 ps position
restrained MD simulations were performed for every system
followed by 5 ns production MD simulations with a time step of 2
fs at constant pressure (1 atm) and temperature (300 K). The
electrostatic interactions were calculated by the PME algorithm
and all bonds were constrained using LINCS algorithm. A twin
range cutoff was used for long-range interactions including 9 A ˚ for
van der Waals and 14 A ˚ for electrostatic interactions. The
snapshots were collected at every 1 ps and stored for further
analyses of MD simulations. The system stability and behavior of
the catalytic structural components present in every system were
analyzed using the tools available with GROMACS 4.5.3 and
PyMol programs.
Generation of hybrid pharmacophore models
Representative structures collected from the MD simulations of
C15 and LTA4 complexes were utilized in the generation of
hybrid 3D pharmacophore hypotheses based on the features
identified from C15 the most active compound and LTA4 the
substrate. The Feature Mapping protocol as available in DS was used
in identifying the pharmacophoric features of C15 and LTA4. An
investigation based on the importance of all generated pharma-
cophoric features was performed to select the features to
complement the very important interaction points at the active
site. Utilization of this hybrid pharmacophore model development
methodology is completely new and different methodology from
the common feature and structure-activity relationship based
pharmacophore models employed in our previous study in
designing hLTA4H inhibitors [33].
Druglike database screening and molecular docking
A druglike database was developed from the commercially
available Maybridge database containing 59632 chemically
diverse compounds using the following procedure [34]. However,
this database is found to have number of nondruglike compounds.
As it is meaningless to dock all the compounds of this database into
the active site of protein target and then reject them in the later
stage for their nondruglike properties, the compounds not
satisfying druglike properties were excluded from the database.
In order to achieve this step, compounds in the Maybridge
database were subjected to various rigorous druglike filters such as
Figure 2. The 2D chemical structures of hLTA4H inhibitors used
in this study along with their IC50 values.
doi:10.1371/journal.pone.0034593.g002
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metabolism, excretion, and toxicity) properties [35]. Finally 4966
compounds were selected to be in the druglike database. The
Prepare Ligands and ADMET Descriptors protocol as available in DS
program were used in this step. This druglike database was used in
database screening to select the compounds containing the hybrid
pharmacophoric features identified from both the inhibitor and
substrate. This virtual screening was conducted to find novel and
diverse virtual leads suitable for further development. Database
searching offers the advantage that the retrieved compounds are
usually more easily available for testing than those based on de novo
design methods [36].
The druglike hit compounds that were identified to have hybrid
pharmacophoric features were subjected to molecular docking
studies. The Prepare Ligands protocol as implemented in DS was
employed to change the ionization states as well as to generate
different tautomers and isomers of the hit compounds. The GOLD
program from Cambridge Crystallographic Data Centre, UK uses
a genetic algorithm to dock the small molecules into the protein
active site. The GOLD allows for a full range of flexibility of the
ligands and partial flexibility of the protein. Protein coordinates
from the representative structure of LTA4H-C15 complex
obtained from MD simulation were used to define the active site.
The active site was defined with a 10 A ˚ radius around the bound
inhibitor. The ten top-scoring conformations of every ligand were
saved at the end of the calculation. Early termination option was
used to skip the genetic optimization calculation when any five
conformations of a particular compound were predicted within an
RMS deviation value of 1.5 A ˚. The GOLD fitness score is
calculated from the contributions of hydrogen bond and van der
Waals interactions between the protein and ligand, intramolecular
hydrogen bonds, and strains of the ligand [37]. Protein-ligand
interactions were analyzed using DS and Molegro Molecule Viewer
[38]. As a further validation, electronic parameters and binding
free energies were calculated for all the known active compounds
and database hits using DMol3 and AutoDock 4.2 programs [39–
41]. The final hit compounds with superior electronic parameters
and binding energies were selected.
Results and Discussion
Selected LTA4H inhibitors
The four LTA4H inhibitors used in this study are very similar in
terms of their chemical structures but their hLTA4H inhibitory
profiles (IC50 values) tested using the same biological assay were
highly deviating with one another (Figure 2). The least active C13
is the S isomer of C14 but the observed IC50 value reduced three
folds for C13 compared to C14. The C5 also displays the same
scaffold as other compounds in the study but its IC50 value was
180 nM which is two folds lower than its counterpart C14
(87 nM). In the other hand, addition of thiophene ring (C15) has
increased the IC50 value of C14 to 21 folds. This high change in
the hLTA4H inhibitory profile of these similar chemical
compounds has increased our interest in studying the structural
reasons explaining this behavior. The identification of structural
responses to these similar inhibitors with different inhibitory
Figure 3. The plots to investigate the stability of the systems. (A) RMSD and (B) potential energy plots.
doi:10.1371/journal.pone.0034593.g003
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inhibition of LTA4H enzyme as novel anti-inflammatory thera-
peutics.
Overall stability of the systems
The MD simulation results of all the systems were used in these
analyses investigating the stability of every system. The stability of
each protein complex during the MD simulation was also
monitored using root mean square deviation (RMSD) calculation
with respect to their initial structure (Figure 3A). The RMSD of
LTA4H-substrate complex has shown the lowest value compared
to all other systems whereas the complex with most active
compound has displayed the highest among other inhibitors.
Though the differences were observed in RMSD values among the
systems, they all have converged at around 2.0 A ˚ except apoform
and C15 complex which had a mean value slightly over 2.0 A ˚.
The higher RMSD value of the C15 complex (2.4 A ˚) depicts the
structural flexibility of the system upon binding of C15 when
compared to others. Comparing the mean RMSD values of C14
and C15, which are 2.0 A ˚ and 2.4 A ˚, respectively, has displayed
the flexibility observed in the structure because of the addition of
thiophene ring in the structure. The calculated mean RMSD
values of R and S isomers (C14 and C13) were 2.01 A ˚ and 2.03 A ˚,
respectively, showing similar stability in these complexes. Inter-
estingly, all complexes other than the most active compound have
shown the RMSD values lesser than that of apoform explaining
the difference in the instability in LTA4H-C15 complex. The
potential energy of the system is also a simple measure of its
stability and thus plots of potential energy as a function of time
were generated to observe the stability of the systems (Figure 3B).
The plots indicated that all the systems in the study were well
equilibrated and remained stable throughout the simulations. The
apoform (21890360 kcal/mol), C13 (21887727 kcal/mol), and
C15 (21890238 kcal/mol) complex systems have shown lower
potential energy values compared to substrate (21867486 kcal/
mol), C5 (21836142 kcal/mol), and C14 (21833350 kcal/mol)
complexes. The root mean square fluctuation (RMSF) values of
the systems were also calculated and plotted to compare the
flexibility of each amino acid residues of the complex. This RMSF
plot has shown the flexible regions of the systems but the focused
RMSF plot has clearly displayed that none of the important
catalytic residues present in the active site has shown an RMSF
value more than 1.4 A ˚ (Figure 4). This result has confirmed that
the catalytic machinery present in the active site was not distorted
upon binding of substrate and any of the inhibitors (Figure 4A).
The amino acids, namely, G269, E296, D375, Y378, and Y383
have shown the flexibility upon the binding of different ligands.
Most of these residues were highly fluctuating in apoform of the
enzyme whereas they were stable in complex systems indicating
the binding nature of the ligands (Figure 4B). In case of C13, C14,
and C15 complexes, R563 and K565 residues were fluctuating
compared to other systems. Particularly, D375 fluctuated more
Figure 4. The RMSF plots of all systems. (A) full protein and (B) important active site residues.
doi:10.1371/journal.pone.0034593.g004
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flexible nature in apoform and inhibitor complexes but not in
substrate complex.
Mode of substrate binding in LTA4H
The substrate LTA4 was docked into the active site of LTA4H
enzyme selected as a representative structure from the MD
simulation of the apoform of the enzyme. Since the crystal
structure of the enzyme-substrate complex has not been
determined yet, the proposed binding mode of the substrate is of
great interest to understand the hydrolase mechanism of the
enzyme. Some previous studies have also proposed its binding
mode at the active site of the enzyme. The active site pocket lined
by the amino acids belong to K21 peptide is around 6–7 A ˚ wide
and stretches 15 A ˚ deeper into the protein [25]. The K21 is a 21
amino acids long peptide segment made of residues between L365
and K385. All the ligands under study bind the same active site
pocket (Figure 5A) but they vary in terms of their molecular
interactions. Particularly the calculated intermolecular hydrogen
bonds have correlated well with the biological activities of the
compounds under study (Figure 6). The proposed binding mode of
LTA4 is observed to have its epoxide moiety close enough to the
Zn
2+ ion whereas the carboxylate group interacts with the
positively charged R563 and K565 residues enabling the catalysis.
The other residues such as Y378 and Y383 also have formed
hydrogen bonds with the substrate (Figure 5B). The intermolecular
hydrogen bonds formed in the enzyme-substrate complex were
increased during the second half of the simulation time indicating
the stronger interactions at the active site (Figure 6A). The long
chain alkyl end of LTA4 is bent and snugly fit into the deeper
hydrophobic cavity formed by residues including W311, F314 and
Y378 as reported earlier [25]. Comparing to the active site of
apoform, the catalytic residues in substrate complex were much
stable except small side chain movements that brought the
charged residues E271, R563, and K565 and the hydrophobic
residues F314, Y378, and Y383 residues near the substrate for
stronger molecular interactions. The lower mean RMSD values of
the substrate complex (1.7 A ˚) also displayed the stable nature of
the system compared to that of apoform (2.2 A ˚). These binding
characteristics observed from the LTA4H-substrate simulation are
compared with the binding modes of inhibitors.
Binding characteristics of LTA4H-inhibitor complexes
LTA4H-C5 complex. This is the second least active
compound among the inhibitors under study containing an
additional methylene group and directly attached to the nitrogen
atom of the five-membered pyrrolidine ring. The C13 and C14 (S
and R isomers) were attached to this pyrrolidine at its second
position whereas C15 differs only with an additional thiophene
ring to its terminal phenyl group compared to C14. The binding
mode of C5 at the active site has not formed any hydrogen bond
with the active site residues throughout the simulation time
indicating its binding with less affinity (Figure 6B). The region of
the active site where the long alkyl chain of the substrate binds was
occupied by both the phenyl rings of C5. But the compound did
not stretch till the region where R563 and K565 residues are
present. This unoccupied region including G269 loop has
fluctuated freely during the simulation (Figure 7A).
LTA4H-C13 complex. The C13 is a shorter compound
compared to C5 because of the additional methylene group in C5.
The binding mode of this compound is also similar to C5 but the
orientation of the central phenyl ring and the position of the
methylene group next to the ether oxygen atom have formed two
strong hydrophobic interactions with the aromatic phenol ring of
Y378 such as p-p and p-s interactions (Figure 7B). Though these
hydrophobic interactions were observed in C13 complex, one or
no hydrogen bonds were formed between protein and ligand
molecules throughout the simulation time (Figure 6B). This is
Figure 5. Binding modes of ligands. (A) Overlay of the binding modes of all the inhibitors at the active site of hLTA4H enzyme. The LTA4, C5, C13,
C14, and C15 complexes were represented in green cyan, violet, dark salmon, slate, and orange colors, respectively. (B) Overlay of the active sites of
apoform and substrate (LTA4) complex of the enzyme. Amino acid residues and bound substrate are shown in stick and ball-stick forms, respectively.
The hydrogen bonds are shown in black dashed lines. The gray and green cyan cartoons represent apoform and LTA4 complexes, respectively.
doi:10.1371/journal.pone.0034593.g005
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the hydrophobic region of the active site where the long alkyl
chain of the substrate binds and did not form any interactions with
the residues from the carboxylate binding region. In terms of
active site flexibility upon binding of C13, the phenyl ring of F314
has moved drastically down near the central phenyl ring of C13
enabling strong hydrophobic interactions. The residues including
Q136, G269, E271, Y378, and Y383 have moved close to the
bound inhibitor whereas the positively charged R563 and K565
residues have moved away from the inhibitor. The whole region of
G269 loop was in high fluctuation during the simulation as there
was no intermolecular contact that stabilized the movement
(Figure 7B).
LTA4H-C14 complex. The C14, which is the R-isomer of
C13, has formed hydrogen bonds with the active site residue Y383
and did not form any of the p interactions as observed in C13
complex. It is because of the orientation of the phenyl rings of the
compound which is completely different to that of C13. The F314
residue that drastically moved down in C13 binding was stable
upon C14 binding whereas Y378 that formed p-p interactions
with C13 has moved close to the pyrrolidine ring of C14 to form
strong hydrophobic interaction. The terminal phenyl ring of this
compound bound deep into the active site region where long alkyl
chain of the substrate binds unlike all other inhibitors. In this case,
Q136 has moved close to the inhibitor within the interacting
distance. This compound also has not reached till the carboxylate
binding region of the enzyme where R563 and K565 residues are
present. The upper region of G269 loop was also highly fluctuating
during the simulation as it was not involved in any intermolecular
interactions (Figure 7C).
LTA4H-C15 complex. The binding mode of C15, the most
active compound, was of high affinity inside the active site of the
enzyme as the binding includes strong hydrogen bond and
hydrophobic interactions. The phenyl ring attached to the
thiophene ring has formed a strong p-p interaction with Y378,
the amino acid residue that moved close to the bound inhibitor
during the simulation. The other phenyl ring attached to the ether
oxygen atom was positioned in such a way to interact
hydrophobically with Y383. Comparing to the positions in
apoform the amino acids including Q136, E271, R563, and
K565 have moved away to accommodate the inhibitor whereas
G269, Y378, and Y383 have moved close to form strong
interactions. One of the charged amino acids R563 and K565
as well as G269 have formed strong hydrogen bond interactions
with the ether oxygen atom and pyrrolidine ring similar to the
interactions observed in substrate binding (Figure 7D). These
hydrogen bond interactions were stable throughout the simulation
and support the experimentally observed potency in LTA4H
Figure 6. Intermolecular hydrogen bond plots. Observed intermolecular hydrogen bonds between (A) the substrate (B) inhibitors and active
site residues.
doi:10.1371/journal.pone.0034593.g006
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binding unlike all other inhibitor complexes and the number of
intermolecular hydrogen bonds observed during the simulation
was also high and stable compared to that of other complexes.
Energetics of LTA4H-ligand complexes
The electrostatic and van der Waals (vdw) energy contributions
to the non-bonded interaction energies of all ligands were
calculated using Calculate Interaction Energy protocol implemented
in DS. The total calculated electrostatic interaction energies were
2130.36, 244.81, 221.58, 215.08, and 91.65 for LTA4, C5,
C13, C14, and C15 complexes, respectively. These interaction
energy values correlate well with the experimental IC50 values
where C15, the most active compound, is with positive energy.
The vdw energy of this compound is higher than all other
compounds and it was not compensated with the electrostatic
energy and thus indicates the destabilizing effect in LTA4H-C15
complex. All other complexes have shown a favorable vdw
interaction energies except substrate complex where the positive
vdw interaction energy was compensated by electrostatic interac-
tion energy.
The focused investigation over the non-bonded interaction
energy contribution by active site residues has shown that some
residues displayed significant effects over ligand binding (Table 1).
One of the positively charged residues R563 that interacts with the
carboxylate moiety of LTA4, the substrate, has shown major
Figure 7. Binding modes and molecular interactions of the four inhibitors. (A) C5 in violet (B) C13 in dark salmon (C) C14 in slate (D) C15 in
orange colors at the active site of hLTA4H enzyme. The hydrogen bond and p-interactions were displayed in black dashed and red solid lines,
respectively. Amino acid residues and inhibitors are shown in stick and ball-stick forms whereas the gray, violet, dark salmon, slate, and orange
cartoons represent C5, C13, C14, and C15 complexes, respectively.
doi:10.1371/journal.pone.0034593.g007
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high electrostatic contribution is because of the interactions
between negatively charged carboxylate group of LTA4 and
positively charged R563 and K565 residues at the active site. The
substrate complex has shown the highest contribution followed by
the most active compound (C15). This residue has contributed
with positive electrostatic energies for least active compounds. The
negatively charged residue E271 has shown positive electrostatic
interaction energies in all the complexes except C15 complex
indicating the importance of this particular residue in contributing
to the biological response. In terms of G269, which is present in
the region where the carboxylate group of substrate binds in the
active site, all the complexes have shown less contributions from
electrostatic interaction energies. However, their vdw energies
have contributed to the interaction energies except C15, which has
gained a high positive charge against G269 explaining the
repulsion between the residue and the inhibitor. The C14 and
C15 compounds have shown favorable electrostatic interaction
energies with D375 when compared to other ligands. The residue
Y378 also has shown favorable electrostatic interaction energies
for C14 and C15 as well as the substrate showing its significance in
ligand binding. Finally, the divalent metal ion present in the active
site has shown favorable interaction energies in all complexes
except C15 complex. This can be explained based on the location
of the oxygen atom of the epoxide group in LTA4 or ether group
in inhibitors. In all complexes except C15, the oxygen atom of the
compound is present close to the divalent cationic metal ion and
thereby leads to the favorable electrostatic interactions whereas in
C15 complex this oxygen atom is away from the metal ion leading
to the positive electrostatic energy. These interaction energy
investigations for the ligands under study have disclosed the
information on the extent of involvement of active site residues
and the part of ligands influencing the interactions at the active site.
Structural changes at the active site
During the MD simulations, significant structural changes were
observed in and around the active site influencing the way critical
residues bind to the ligands. The first change observed was over the
variable region formed by residues V306-N308 of the catalytic
domain in apoform (Figure 8). This variable region has formed a
small beta-strand upon binding of the substrate and all inhibitors
except C14 (Figures 8 and 9). This change in the loop has brought
significant conformational change upon the important F314 residue
especially in LTA4H-C13 complex. This small beta-strand forma-
tion was not observed in the complex of C14, which is the R-isomer
of C13 indicating the effect upon isomeric differences (Figure 9C).
The another variable region close to the V306-N308 was also
observed to form a small beta-strand but this was not significant as it
was present away from the active site and has not influenced any of
the active site residues indirectcontact with the binding ligands.The
Table 1. Calculated non-bonded interaction energies between the inhibitors and important active site residues.
Residue LTA4 CPD5 CPD13 CPD14 CPD15
vdw Elec vdw Elec vdw Elec vdw Elec vdw Elec
Q136 2.15 2.25 23.67 20.26 21.78 21.24 4.60 6.26 21.38 2.21
G269 20.30 3.82 21.39 0.66 20.67 0.97 20.88 1.21 130.3 4.32
E271 20.91 30.67 20.49 7.82 20.47 2.53 20.43 3.70 20.38 26.39
E296 20.03 32.47 20.11 22.90 20.06 20.91 0.00 21.10 20.49 22.68
F314 24.58 21.78 22.27 21.67 23.66 2.97 22.30 2.13 22.35 1.23
D375 21.84 20.19 20.90 0.87 21.75 1.77 20.85 23.56 22.29 25.21
Y378 18.18 218.05 24.02 0.97 1.43 0.56 22.69 23.70 25.51 22.31
Y383 1.31 23.58 22.50 5.19 20.19 1.45 20.89 20.99 21.31 20.24
R563 22.47 2109.48 20.09 2.85 20.15 22.40 20.03 0.34 21.37 23.40
K565 3.04 260.89 20.16 23.21 20.99 23.36 20.02 6.79 20.21 22.65
Zn
2+ 20.14 286.01 20.09 27.16 20.12 212.11 20.08 215.85 20.07 2.17
vdw – van der Waal; Elec – electrostatic.
doi:10.1371/journal.pone.0034593.t001
Figure 8. The structural changes observed between the active
site regions of apoform (grey) and hLTA4H-substrate complex
(green cyan). The amino acid residues are shown in thin stick form
and bound substrate is shown in ball-stick form. The hydrogen atoms
were hidden for clarity.
doi:10.1371/journal.pone.0034593.g008
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the helix formed by S379-L397 residues from the catalytic domain.
In the apoform and upon substrate binding this helix remained
unchanged (Figure 8) whereas upon the binding of inhibitors except
C15, this long helix was extended by one to three amino acids. In
case of C5 and C13 binding, this long helix was formed by the
residues S379-L397 extended by three amino acids from S379-V381
whereas in C14 complex only one amino acid residue V381 involve
in the formation of the long helix (Figure 9C). In C15 complex no
change on the helix was observed and remained the same as
observed in apoform and substrate complex (Figure 9D). These
changesobservedinallthesystemshavedisplayedatrendexplaining
the IC50 values of the compounds. The least active compounds C5
and C13 complexes have included three amino acid residues in the
helix extension whereas the intermediate active compound C14 has
extended the helix with one additional residue. In case of C15
complex, the helix has remained the same as in apoform and
substrate complexes. Thus the conformational changes in this helix
Figure 9. The structural changes observed at the active site region of the systems. (A) C5 (B) C13 (C) C14 and (D) C15 complexes. The
amino acid residues are shown in thin stick form and bound inhibitors are shown in ball-stick form. The hydrogen atoms were hidden for clarity.
doi:10.1371/journal.pone.0034593.g009
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activity of the inhibitor. This amino acid residue positions its
phenolic ring close to the hydrophobic phenyl rings present in the
inhibitors enabling strong p-interactions at the active site.
The third significant change observed at the active site includes
the very important region of the active site that reported to be
involved in both the activities of the bi-functional LTA4H enzyme.
This region interacts with the ligands especially the substrate
through positively charged residues R563 and K565. These amino
acids present at the edge of the helix formed by T567-A576
residues from the C-terminal regions. During the simulation of the
systems, the conformational change over this helix was observed.
The edge of this helix where K565 was present has maintained the
same in apoform as well as in substrate and active compound (C14
and C15) complexes. An extension of the T567-A576 helix was
observed in the least compound complexes including the K565
edge and thereby rendering the positive charged amino acid
restrained and away from the inhibitor.
Hybrid pharmacophore model generation and virtual
screening
The representative structure obtained from the MD simulation
trajectories of LTA4H-C15 complex was used in generating a
pharmacophore model. The Feature Mapping protocol has generated
all the pharmacophoric features present in the bound conformation
of this most active compound at the active site of hLTA4H. The
initial pharmacophore model has included overlapping ring
aromatic (RA) and hydrophobic (HY) features on the phenyl and
thiophene ringsoftheinhibitorsas well astheoverlappinghydrogen
bond donor (HBD) and positive ionizable (PI) features over the
nitrogen atom of pyrrolidine ring. The overlapping ring aromatic
features were removed to simplify the pharmacophore model. Thus
the final pharmacophore model included three HY, two HBA, and
a PI or HBD features (Figure 10A). The PI feature generated from
the nitrogen atom of pyrrolidine ring of C15 found to be repelled by
the two positively charged amino acid residues R563 and K565 at
the active site. These residues are very important for both the
functions of LTA4H and reported to position the substrate at the
active site for the effective catalysis [28]. The presence of negative
ionizable (NI) or hydrogen bond acceptor (HBA) groups instead of
PI or HBD groups can improve the binding of ligand by forming
strong molecular interactions with these positively charged residues
(Figure 10B). Hence two hybrid pharmacophore models containing
all the features except PI and HBD generated from the binding
mode of C15 and either a NI or HBA feature generated from LTA4
binding mode were developed (Figure 10C and 10D). Two
Figure 10. Development of hybrid pharmacophore models. The pharmacophore model generated from the binding modes of (A) C15 and (B)
LTA4. The amino acid residues of the enzyme are shown in gray thin stick form whereas the bound C15 and LTA4 are shown in thick stick form. The
secondary structure cartoon of the protein is colored based on the hydrophobicity of the amino acid residues. (C) Pharm-A (D) Pharm-B, the final
hybrid pharmacophore models.
doi:10.1371/journal.pone.0034593.g010
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HBA (Pharm-B) feature were developed in order to screen the
chemical compounds with NI or HBA feature as present in LTA4.
These final pharmacophore models were used as 3D structural
queries in screening Maybridge drug-like database containing 4966
chemical compounds prepared earlier [42]. From the database
screening, 7 and 226 compounds mapping all the six features of the
pharmacophore model were identified by the models with NI and
HBA, respectively. Finally, a total of 233 compounds satisfying all
the filters were selected and subjected to the molecular docking
calculations using GOLD program.
Molecular docking
A total of 233 compounds identified from the database screening
along with the four experimentally known compounds were docked
in to the active site of hLTA4H using the representative structure of
hLTA4H-C15 complex obtained from MD simulation. Interest-
ingly the most active compound (C15) has scored a GOLD_Fitness
value of 70.12 which is greater than other three compounds. The
GOLD program was validated for its performance for hLTA4H
enzyme based on the RMSD difference observed between X-ray
bound and docked poses of a particular inhibitor [33]. From these
docking results, 51 compounds with a GOLD_Fitness value greater
than 70 were selected. A total of 18 compounds were selected based
on the binding mode and better molecular interactions with active
site components compared to that of C15 (Table 2).
As an effective post-docking filtering protocol, the electronic
parameters such as highest occupied molecular orbital (HOMO),
least unoccupied molecular orbital (LUMO), and energy gap (DE)
values along with the binding free energies were calculated for all
compounds. The calculated energy gap values have highly
correlated the experimental activities of the four compounds used
in the study. A lowering trend over energy gap was observed
against the experimental activity values. Thus the compounds
scoring lower energy gap values than the most active compound
were selected and subjected to another molecular docking
procedure using Autodock program. The binding free energy
values were calculated for all the compounds and three hit
compounds scoring a better binding free energy values than the
inhibitor compounds were selected (Table 2).
The binding conformation of the C15 has formed hydrogen
bonds with catalytically important R563 and G269 residues
through its pyrrolidine nitrogen and oxygen atoms that mapped
over the PI and HBD features. The central phenyl ring present in
this inhibitor has formed a strong p-cation interaction with
divalent metal ion (Zn
2+) (Figure 11A). Finally 3 hit compounds
showing favorable GOLD_Fitness, Autodock binding free energy,
and highly reactive electronic parameters along with strong
molecular interactions were selected and reported as the final
inhibitory leads from this study. All of these three final hit
compounds were identified through the Pharm-B containing the
HBA feature derived from the substrate binding. Five out of seven
compounds retrieved through Pharm-A failed to make important
molecular interactions and the remaining two compounds (H17
and H18) were rejected based on the Autodock binding free
energy (Table 2).
Binding mode of Hit 1. This hit compound has shown a
different binding mode compared to that of C15, the most active
Table 2. Results of molecular docking using GOLD and Autodock programs along with some of the electronic parameters
calculated for the known inhibitors and hit compounds.
Name* Ligand GOLD fitness Binding free energy kcal/mol HOMO (eV) LOMO (eV) Energy gap (eV)
C15 C15 70.120 210.86 20.175 20.054 0.121
C14 C14 60.090 29.71 20.171 20.044 0.127
C5 C5 59.800 29.80 20.167 20.034 0.133
C13 C13 62.210 29.92 20.180 20.036 0.144
H1 BTB_01185 72.669 210.34 20.280 20.234 0.046
H2 HTS_05216 72.383 210.04 20.100 20.082 0.018
H3 GK_03083 76.419 29.94 20.305 20.196 0.108
H4 BTB_11904 75.583 29.49 20.206 20.144 0.062
H5 SCR_00085 72.921 29.49 20.192 20.054 0.138
H6 HTS_08249 73.682 29.31 20.187 20.063 0.124
H7 AW_01216 71.342 29.15 20.117 20.083 0.034
H8 HTS_05096 71.885 28.82 20.189 20.093 0.096
H9 SEW_01301 72.913 28.79 20.294 20.224 0.070
H10 KM_10589 75.912 28.46 20.203 20.077 0.127
H11 HTS_11258 73.985 28.22 20.279 20.250 0.029
H12 HTS_12876 72.253 28.03 20.165 20.078 0.087
H13 SPB_06794 71.083 27.92 20.211 20.122 0.089
H14 HTS_12876 72.200 27.67 20.151 20.086 0.065
H15 HTS_13003 70.894 27.66 20.254 20.184 0.070
H16 KM_10378 70.723 27.63 20.177 20.065 0.112
H17 RJC_02521 71.720 26.50 20.135 20.127 0.008
H18 HTS_00131 76.041 26.16 0.007 0.036 0.029
*H1 - Hit 1.
doi:10.1371/journal.pone.0034593.t002
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This hit compound has scored a GOLD_Fitness value of 72.669,
which is higher than that of C15 but their estimated Autodock
binding free energy values were very similar. The molecular
interactions observed at the active site included a strong hydrogen
bond network and hydrophobic interactions. The hydrogen bond
Figure 11. Molecular docking results. The binding modes (A) C15 (B) Hit 1 (C) Hit 2 and (D) Hit 3 at the active site of the enzyme. The amino acid
residues and bound ligands are shown in thin and thick stick representations. The hydrogen bond, co-ordinate bond, and p-interactions are shown in
green dashed, blue solid and red solid lines.
doi:10.1371/journal.pone.0034593.g011
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residues through the ester, oxygen atoms of pyrrolidinone ring,
and amino groups present in the compound. A coordinate bond
was formed between the metal ion and the primary amino group.
The hydrophobic interactions included two p-cation interactions
with H299 (not shown in figure) and K565 residues (Figure 11B).
This compound is a derivative of pyrrolidinone substituted with
two ethyl ester moieties (Figure 12).
Binding mode of Hit 2. This compound has bound the
active site similar to the highly active inhibitor (C15) and formed
hydrogen bond interactions with the same set of residues as
observed in C15 complex. The hydrogen bond network included
the interactions with G269, R563, and K565 residues through the
carboxyl and carbonyl groups present in the compound. Strong
hydrophobic interactions including a p-cation interaction were
observed with Y267 (not shown) and Y383 residues through the
same nitrogen atom of piperazine ring (Figure 11C). This hit
compound is a derivative of piperidine with bulky substitutions
such as benzodioxol groups (Figure 12). The GOLD_Fitness score
and Autodock binding free energy values for this compound were
72.383 and 210.04 kcal/mol, respectively. The lower energy gap
value was also promising for this compound and increased the
reliability to be a potential lead candidate.
Binding mode of Hit 3. The molecular interactions
exhibited by this hit compound included the hydrogen bond
interactions with Y378, Y383, and R563 residues through the
ester, sulphur atom of thiophene ring, and amido groups of the
compound. Like other hits, Hit 3 has also formed strong
hydrophobic interactions such as p-p and p-cation interactions
with Y378 (Figure 11D). The GOLD_Fitness score and Autodock
binding free energy values of this hit compound were 76.419 and
29.94, respectively. This compound is also a derivative of
piperazine but with highly different substitutions of thiophene
and chlorophenyl groups (Figure 12).
The identified compounds were subjected to novelty study using
SciFinder Scholar [43] and PubChem Structure search tools [44]. This
study has confirmed that the identified hits were not reported
elsewhere earlier for the inhibition of hLTA4H. These compounds
remain virtually identified compounds and the experimental
verification of these compounds is required to confirm their
inhibitory profiles. The experimental validations of the final hit
compounds will be performed in the future using one of the
biological assays reported in the literature.
Conclusions
The hLTA4H enzyme catalyzes hydrolase and aminopeptidase
functions by employing its single overlapping binding site. Its
hydrolase function converts the epoxy substrate LTA4 to LTB4, a
highly potent inflammatory activator of LT cascade. Thus diverse
hLTA4H inhibitors were developed by different research groups
searching for a most potent anti-inflammatory agent. We selected
four structurally similar compounds but diverse in terms of
hLTA4H inhibitory profiles to be used in this study aiming at
finding the reasons for the difference observed in their inhibitory
profiles brought by the small structural difference. The differences
in binding modes of the inhibitors along with the hydrogen bond
networks and non-bonded interaction energies between the
inhibitor and catalytic residues have effectively scripted the
differences in the activity. The hydrogen bond network compar-
ison has revealed that the most active compound has formed the
hydrogen bond interactions with the positively charged R563 and
K565 residues at the active site. These residues were reported to
hold the substrate at a particular conformation in such a way that
the epoxy group of the substrate binds close to the catalytic
machinery and thus the hydrogen bond interaction formed by an
inhibitor is considered very essential for inhibitor binding. The
structural changes include the secondary structural changes
observed at the regions of V306-N308, S379-Y383, and K565
residues that determine the conformation and flexibility of very
important catalytic F314, Y378, Y383, and K565 residues.
Interestingly, the region of K565 has become more flexible in
substrate as well as most active C14 and C15 complexes whereas
this region has become rigid by the formation of helix in least
active C5 and C13 complexes. The flexibility of F314 residue is
different in most active complex (hLTA4H-C15) by forming a
helix but not in other complexes. In S379-Y383 region, all of these
five residues were present in variable regions but two residues were
in variable regions in C14 complex and in least active complexes
almost all the residues were involved in helix formation. These
observed differences in binding modes, structural changes, and
hydrogen bond networks explained the reasons for the potent
inhibitory profile of C15, slightly reduced activity of C14, and least
active nature of C5 and C13. The dynamic structures of hLTA4H-
C15 and hLTA4H-LTA4 complexes were used in the develop-
ment of two hybrid pharmacophore models and employed in
database screening to find potential lead candidates with the
pharmacophoric features from both C15 and LTA4. The database
hit compounds were further filtered based on the molecular
docking results and electronic parameters such as energy gap
values. Finally three compounds containing all the identified
hybrid features were selected to be used in designing novel and
potent hLTA4H inhibitors.
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